

## Supplementary materials

1. Full search strategy
2. Excluded studies table with reasons
3. Signalling questions for risk of bias assessment

### Supplement 1. Full search strategy for all databases run on 08/04/2020 and updated on 14/05/2020

#### PubMed search

((("COVID-19"[Supplementary Concept] OR "COVID-19"[tiab] OR COVID19[tiab] OR "COVID 19"[tiab] OR "SARS-CoV-2"[tiab] OR "2019-nCoV"[tiab] OR "Novel coronavirus"[tiab] OR "Coronavirus 2019"[tiab] OR "Coronavirus 19"[tiab] OR "COVID 2019"[tiab] OR "2019 ncov"[tiab] OR "Wuhan coronavirus"[tiab])

AND

("Asymptomatic Diseases"[Mesh] OR Asymptomatic[tiab] OR Presymptomatic[tiab] OR "Pre-Symptomatic"[tiab] OR "No symptoms"[tiab] OR "No symptom"[tiab] OR "Silent transmission"[tiab] OR "Silent carrier"[tiab] OR "Silent carriers"[tiab])

AND

(Letter[pt] OR "Epidemiologic Studies"[Mesh] OR "Case-control studies"[Mesh] OR "Cohort Studies"[Mesh] OR "Case control"[tiab] OR Longitudinal[tiab] OR Prospective[tiab] OR Retrospective[tiab] OR "Cross sectional"[tiab] OR "Cross-Sectional Studies"[Mesh] OR Investigated[tiab] OR Analysis[tiab] OR Data[tiab] OR Cases[tiab] OR Ratio[tiab] OR "statistics and numerical data"[sh] OR "epidemiology"[sh]))

OR

((("COVID-19"[ti] OR COVID19[ti] OR "COVID 19"[ti] OR "SARS-CoV-2"[ti] OR "2019-nCoV"[ti] OR "Novel coronavirus"[ti] OR "Coronavirus 2019"[ti] OR "Coronavirus 19"[ti] OR "COVID 2019"[ti] OR "2019 ncov"[ti] OR "Wuhan coronavirus"[ti])

AND

(Asymptomatic[ti] OR Presymptomatic[ti] OR "Pre-Symptomatic"[ti]))

AND ("2019/01/01"[PDat] : "2020/12/31"[PDat])

#### Embase search

((COVID-19:ti,ab OR COVID19:ti,ab OR "COVID 19":ti,ab OR SARS-CoV-2:ti,ab OR 2019-nCoV:ti,ab OR "Novel coronavirus":ti,ab OR "Coronavirus 2019":ti,ab OR "Coronavirus 19":ti,ab OR "COVID 2019":ti,ab OR "2019 ncov":ti,ab OR "Wuhan coronavirus":ti,ab)

AND

('asymptomatic disease'/exp OR Asymptomatic:ti,ab OR Presymptomatic:ti,ab OR Pre-Symptomatic:ti,ab OR "No symptoms":ti,ab OR "No symptom":ti,ab OR "Silent transmission":ti,ab OR "Silent carrier":ti,ab OR "Silent carriers":ti,ab)

AND

('letter'/exp OR 'epidemiology'/exp OR 'case control study'/exp OR 'cohort analysis'/exp OR "Case control":ti,ab OR Longitudinal:ti,ab OR Prospective:ti,ab OR Retrospective:ti,ab OR "Cross sectional":ti,ab OR 'cross-sectional study'/exp OR Investigated:ti,ab OR Analysis:ti,ab OR Data:ti,ab OR Cases:ti,ab OR Ratio:ti,ab))

OR

((COVID-19:ti OR COVID19:ti OR "COVID 19":ti OR SARS-CoV-2:ti OR 2019-nCoV:ti OR "Novel coronavirus":ti OR "Coronavirus 2019":ti OR "Coronavirus 19":ti OR "COVID 2019":ti OR "2019 ncov":ti OR "Wuhan coronavirus":ti)

AND

(Asymptomatic:ti OR Presymptomatic:ti OR Pre-Symptomatic:ti))

AND [2019-2020]/py

#### Cochrane Covid-19 study register

"Asymptomatic Diseases" OR "Viral Load" OR Asymptomatic OR Presymptomatic OR Pre-Symptomatic OR "No symptoms" OR "No symptom" OR "Silent transmission" OR "Silent carrier" OR "Silent carriers"

#### MedRxiv (pre-print servers) search via Europe PMC

(COVID-19 OR COVID19 OR "COVID 19" OR SARS-CoV-2 OR 2019-nCoV OR "Novel coronavirus" OR "Coronavirus 2019" OR "Coronavirus 19" OR "COVID 2019" OR "2019 ncov" OR "Wuhan coronavirus")

AND

(Asymptomatic OR Presymptomatic OR "No symptoms" OR "No symptom" OR "Silent transmission" OR "Silent carrier" OR "Silent carriers")

## Supplement 2. Excluded studies after full text assessment with reasons

#	Reference	Reason for exclusion	Country
1	Tian S, et al., Characteristics of COVID-29 infection in Beijing, <i>J Infect</i> 80, 401-406	Unclear sampling frame	China
2	Chen, P., et al., Epidemiological and clinical characteristics of 136 cases of COVID-19 in main district of Chongqing. <i>J Formos Med Assoc</i> , 2020.	Unclear sampling frame	China
3	Feng, T., et al., A study on the clinical characteristics and management of patients with mild cases of COVID-19 in shelter hospitals from China. 2020, Research Square.	Unclear sampling frame	China
4	He, G., et al., The clinical feature of silent infections of novel coronavirus infection (COVID-19) in Wenzhou. <i>J Med Virol</i> , 2020.	Unclear sampling frame	China
5	Mandić-Rajčević, S., et al., Contact tracing and isolation of asymptomatic spreaders to successfully control the COVID-19 epidemic among healthcare workers in Milan (Italy). 2020, medRxiv	Unclear sampling frame	Italy
6	Du W, Clinical characteristics of COVID-19 in children compared with adults in Shandong Province, China. <i>Infection</i> , 2020	Unclear sampling frame	China
7	Ben-Ami, R., et al., Large-scale implementation of pooled RNA-extraction and RT-PCR for SARS-CoV-2 detection. 2020, medRxiv.	Unclear sampling frame	Israel
8	An, P., et al., Asymptomatic Patients with Novel Coronavirus Disease (COVID-19). <i>Balkan Med J</i> , 2020.	Unclear sampling frame	China
9	Chau, N.V.V., et al., The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. 2020, medRxiv.	Unclear sampling frame	Vietnam
10	Breslin, N., et al., Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. <i>American Journal of Obstetrics and Gynecology MFM</i> , 2020.	Unclear sampling frame	USA
11	Wang Z, M.W.Z.X.W.G.Z.R., Household Transmission of SARS-CoV-2. <i>Journal of infection</i> , 2020.	Unclear sampling frame	China
12	Wong J, et a., High proportion of asymptomatic and presymptomatic COVID-19 infections in travelers and returning residents to Brunei. <i>Journal of travel medicine</i> , 2020	Unclear sampling frame	Brunei
13	Kim Se, et al., Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients. <i>International journal of infectious diseases</i> , 2020.	Unclear sampling frame	Korea
14	Liao J, et al., Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults	Unclear sampling frame	China
15	Corman, V., et al., SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission. 2020, medRxiv.	Unclear sampling frame	Germany
16	Day, M., Covid-19: four fifths of cases are asymptomatic, China figures indicate. <i>Bmj</i> , 2020. 369: p. m1375.	Unclear sampling frame	China
17	Day, M., Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village. <i>Bmj</i> , 2020. 368: p. m1165.	Unclear sampling frame	Italy
18	Mizumoto, K., et al., Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. <i>Euro Surveill</i> , 2020. 25(10).	Unclear sampling frame	Japan
19	Qiu, C., et al., Transmission and clinical characteristics of coronavirus disease 2019 in 104 outside-Wuhan patients, China. 2020, medRxiv.	Unclear sampling frame	China
20	Tao, Y., et al., High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China. 2020, medRxiv.	Unclear sampling frame	China
21	Tian, S., et al., Characteristics of COVID-19 infection in Beijing. <i>J Infect</i> , 2020. 80(4): p. 401-406.	Unclear sampling frame	China
22	Zhang, Z., et al., Clinical characteristics of COVID-19 in children compared with adults in Shandong, China. 2020, Research Square.	Unclear sampling frame	China
23	Feng, K., et al., [Analysis of CT features of 15 children with 2019 novel coronavirus infection]. <i>Zhonghua Er Ke Za Zhi</i> , 2020. 58(4): p. 275-278.	Unclear sampling frame	China
24	Nishiura H, Kobayashi T, Suzuki A, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). <i>International Journal of Infectious Diseases</i> 2020.	Unclear sampling frame	Japan
25	Lytras T, Dellis G, Flountzi A, et al. High prevalence of SARS-CoV-2 infection in repatriation flights to Greece from three European countries. <i>Journal of Travel Medicine</i> 2020.	Unclear sampling frame	Greece
26	Zhou, X., et al., Follow-up of the asymptomatic patients with SARS-CoV-2 infection. <i>Clin Microbiol Infect</i> , 2020.	Unclear sampling frame	China
27			
28	Fontanet, A., et al., Cluster of COVID-19 in northern France: A retrospective closed cohort study. 2020, medRxiv.	No/Unclear follow-up period	France

29	Jing, Q.L., et al., [Contagiousness and secondary attack rate of 2019 novel coronavirus based on cluster epidemics of COVID-19 in Guangzhou]. <i>Zhonghua Liu Xing Bing Xue Za Zhi</i> , 2020. <b>41</b> (0): p. E058	No/Unclear follow-up period	China
30	Lao, X., et al., Epidemiological characteristics and the effectiveness of countermeasures to control coronavirus disease 2019 in Ningbo City, China. 2020, Research Square.	No/Unclear follow-up period	China
31	Streeck, H., et al., Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. 2020, medRxiv.	No/Unclear follow-up period	Germany
32	Just, J., et al., Distinguishing between COVID-19 and the common cold in a primary care setting - comparison of patients with positive and negative SARS-CoV-2 PCR results. 2020, medRxiv.	No/Unclear follow-up period	Germany
33	Kim, H., H. Hong, and S.H. Yoon, Diagnostic Performance of CT and Reverse Transcriptase-Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis. <i>Radiology</i> , 2020: p. 201343.	No/Unclear follow-up period	Various
34	Kim Gu, et al., Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. <i>Clinical microbiology and infection</i> , 2020.	No/Unclear follow-up period	Korea
35	Tabata, S., et al., The clinical characteristics of COVID-19: a retrospective analysis of 104 patients from the outbreak on board the Diamond Princess cruise ship in Japan. 2020, medRxiv.	No/Unclear follow-up period	Japan
36	Dong, Y., et al., Epidemiology of COVID-19 Among Children in China. <i>Pediatrics</i> , 2020.	No/Unclear follow-up period	China
37	Day M, COVID-19: Four fifths of cases are asymptomatic, China figures indicate	No/Unclear follow-up period	China
38	Rivett, L., et al., Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. <i>Elife</i> , 2020. <b>9</b> .	No/Unclear follow-up period	England
39	McMichael T, et al., Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington	No/Unclear follow-up period	USA
40	Zhonghua, L., B. Xing, and Z.Z. Xue, [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. 2020. <b>41</b> (2): p. 145-151.	No/Unclear follow-up period	China
41	Hu, Z., et al., Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. <i>Sci China Life Sci</i> , 2020.	No/Unclear follow-up period	China
42	Liao, J., et al., Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults. 2020, medRxiv.	No/Unclear follow-up period	China
43	Ling, Z., et al., Asymptomatic SARS-CoV-2 infected patients with persistent negative CT findings. <i>Eur J Radiol</i> , 2020. <b>126</b> : p. 108956.	No/Unclear follow-up period	China
44	Lu, J., et al., A New Features of SARS-CoV-2 Infection in Wenzhou, China. 2020, Research Square.	No/Unclear follow-up period	China
45	Ma, S., et al., Epidemiological parameters of coronavirus disease 2019: a pooled analysis of publicly reported individual data of 1155 cases from seven countries. 2020, medRxiv.	No/Unclear follow-up period	Various
46	Park, S.W., et al., The time scale of asymptomatic transmission affects estimates of epidemic potential in the COVID-19 outbreak. 2020, medRxiv.	No/Unclear follow-up period	USA
47	Qiu, H., et al., Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. <i>Lancet Infect Dis</i> , 2020.	No/Unclear follow-up period	China
48	Shi, H., et al., Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. <i>The Lancet Infectious Diseases</i> , 2020. <b>20</b> (4): p. 425-434.	No/Unclear follow-up period	China
49	Sun, W.W., et al., [Epidemiological characteristics of 2019 novel coronavirus family clustering in Zhejiang Province]. <i>Zhonghua Yu Fang Yi Xue Za Zhi</i> , 2020. <b>54</b> (0): p. E027.	No/Unclear follow-up period	China
50	Wang, Y., et al., Clinical Implications of 37 Childhood Cases with 2019-nCoV Infection in Shenzhen, China. 2020, Research Square.	No/Unclear follow-up period	China
51	Chen, J., et al., Clinical progression of patients with COVID-19 in Shanghai, China. <i>Journal of infection</i> , 2020.	No/Unclear follow-up period	China
52	Nakazawa, E., H. Ino, and A. Akabayashi, Chronology of COVID-19 cases on the Diamond Princess cruise ship and ethical considerations: a report from Japan. <i>Disaster Med Public Health Prep</i> , 2020: p. 1-27.	No/Unclear follow-up period	Japan
53	Su, L., et al., The different clinical characteristics of corona virus disease cases between children and their families in China - the character of children with COVID-19. <i>Emerg Microbes Infect</i> , 2020. <b>9</b> (1): p. 707-713.	No/Unclear follow-up period	China
54	Xu, Y., et al., Clinical Characteristics of SARS-CoV-2 Pneumonia Compared to Controls in Chinese Han Population. 2020, medRxiv.	No/Unclear follow-up period	China
55	Zhang, J., et al., Epidemiological and clinical characteristics of imported cases with COVID-19 infection: a multicentre study. 2020, Research Square.	No/Unclear follow-up period	China

56	Gudbjartsson, D.F., et al., Spread of SARS-CoV-2 in the Icelandic Population. <i>N Engl J Med</i> , 2020.	No/Unclear follow-up period	Iceland
57	Sutton, D., et al., Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. <i>New England Journal of Medicine</i> , 2020.	No/Unclear follow-up period	USA
58	Dong Y, et al. Epidemiology of COVID-19 among children in China. <i>Pediatrics</i> . 2020;145(6):e20200702	No/Unclear follow-up period	China
59	Gao, Y., et al., A cluster of the Corona Virus Disease 2019 caused by incubation period transmission in Wuxi, China. <i>Journal of Infection</i> , 2020.	small cluster, only 1 index case	China
60	Bai, Y., et al., Presumed Asymptomatic Carrier Transmission of COVID-19. <i>Jama</i> , 2020.	Small cluster, only 1 index case	China
61	Ki, M., Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea. <i>Epidemiol Health</i> , 2020. 42: p. e2020007.	Small cluster, only 1 index case	Korea
62	Qian G, et al., COVID-19 transmission within a family cluster by presymptomatic infectors in China	Small cluster	China
63	Danis K, et al., Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020. <i>Clinical infectious diseases</i> , 2020.	Small cluster	France
64	Ye X Delivery of infection from asymptomatic carriers of COVID-19 in a familial cluster	Small cluster	China
65	Bai, S.L., et al., [Analysis of the first cluster of cases in a family of COVID-19 in Gansu Province]. <i>Zhonghua Yu Fang Yi Xue Za Zhi</i> , 2020. 54(5): p. 491-493.	Small cluster	China
66	Le, T.Q.M., et al., Severe Acute Respiratory Syndrome Coronavirus 2 Shedding by Travelers, Vietnam, 2020. <i>Emerg Infect Dis</i> , 2020. 26(7).	Small cluster	Vietnam
67	Zhao, D., et al., Clinical characteristics of 10 children with COVID-19 outside of Wuhan in Hubei Province. 2020, Research Square.	Small cluster	China
68	Pan, X., et al., Asymptomatic cases in a family cluster with SARS-CoV-2 infection. <i>The Lancet Infectious Diseases</i> , 2020. 20(4): p. 410-411	Small cluster	China
69	de Souza, T.H., et al., Clinical Manifestations of Children with COVID-19: a Systematic Review. 2020, medRxiv.	Review	Various
70	Wang, X.F., et al., [Retracted: Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen]. <i>Zhonghua Er Ke Za Zhi</i> , 2020. 58(0): p. E008.	Retracted	China
71	Wang, Z., et al., Clinical Characteristics of Children with COVID-19: A Rapid Review and Meta-Analysis. 2020, medRxiv.	No primary study/review	Various
72	Castagnoli, R., et al., Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. <i>JAMA Pediatrics</i> , 2020.	No primary study/review	Various
73	Buitrago-Garcia, D., et al., The role of asymptomatic SARS-CoV-2 infections: rapid living systematic review and meta-analysis. 2020, medRxiv.	No primary study/review	Various
74	Abduljalil, J.M. and B.M. Abduljalil, Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view. <i>New Microbes and New Infections</i> , 2020. 35.	No primary study/review	Various
75	Aguirre-Duarte, N., Can people with asymptomatic or pre-symptomatic COVID-19 infect others: a systematic review of primary data. 2020, medRxiv	No primary study/review	Various
76	The Economist . What's gone wrong with COVID-19 testing in Britain	No primary study/review	England
77	Gilroy R, already stretched care homes 'must prepare to go beyond' for COVID-19	No primary study/review	Various
78	Hu, Z.B. and C. Song, [Screening and management of asymptomatic infection of 2019-novel coronavirus]. <i>Zhonghua Yu Fang Yi Xue Za Zhi</i> , 2020. 54(5): p. 484-485.	No primary study/review	Various
79	Li, H., Z. Liu, and J. Ge, Scientific research progress of COVID-19/SARS-CoV-2 in the first five months. <i>J Cell Mol Med</i> , 2020.	No primary study/review	Various
80	He, W., G. Yi, and Y. Zhu, Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID-19: Meta-analysis and sensitivity analysis. 2020, medRxiv.	No primary study/review	Multiple
81	Woodcock A, Coronavirus: fewer than one in 50 NHS frontline staff forced to stay home have been tested	No primary study/review	England
82	Yamahata Y, S.A., Preparation for the Quarantine of The Diamond Princess Cruise Ship for COVID-19 in Japan: study Design. <i>JMIR public health and surveillance</i> , 2020.	No primary study/review	Japan
83	Wang, Y., et al., Asymptomatic Cases with SARS-CoV-2 Infection. <i>J Med Virol</i> , 2020.	No primary study/review	Various
84	Hu, Z.B. and C. Ci, [Screening and management of asymptomatic infection of corona virus disease 2019 (COVID-19)]. <i>Zhonghua Yu Fang Yi Xue Za Zhi</i> , 2020. 54(0): p. E025.	No primary data	China
85	Dipesh Navsaria, M. and M. MSLIS, Epidemiology of Pediatric Patients With COVID-19 in China	No primary data	China

86	Song, H., et al., A considerable proportion of individuals with asymptomatic SARS-CoV-2 infection in Tibetan population. 2020, medRxiv.	No contact tracing & Asymptomatic on antiviral Rx	Tibet
87	Wang, D., et al., [Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China]. Zhonghua Er Ke Za Zhi, 2020. 58(4): p. E011.	No contact tracing & Asymptomatic on antiviral Rx	China
88	Donida, B.M., Report on the new coronavirus Covid-19 pandemic in Italy. 2020, Research Square.	No asymptomatic data	Italy
89	Li Q, et al., Early transmission dynamics in Wuhan, China, of Novel Coronavirus - Infected pneumonia	No asymptomatic data	China
90	Chen Cm, et al., Containing COVID-19 among 627,386 Persons Contacting with Diamond Princess Cruise Ship Passengers Disembarked in Taiwan: big Data Analytics. Journal of medical Internet research, 2020	No asymptomatic data	Taiwan
91	Forouzesh, M., et al., Clinical display, diagnostics and genetic implication of novel Coronavirus (COVID-19) epidemic. Eur Rev Med Pharmacol Sci, 2020. 24(8): p. 4607-4615.	No asymptomatic data	Various
92	He, D., et al., The relative transmissibility of asymptomatic COVID-19 infections among close contacts. International Journal of Infectious Diseases, 2020. 94: p. 145-147.	No asymptomatic data	China
93	Garcia-Basteiro, A., et al., Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. 2020, medRxiv.	No asymptomatic data	Spain
94	Philip P et al., Testing of NHS staff and household members	No asymptomatic data	England
95	Ji, T., et al., Lockdown contained the spread of 2019 novel coronavirus disease in Huangshi city, China: Early epidemiological findings. Clin Infect Dis, 2020	No asymptomatic data	China
96	WHO Coronavirus Disease Situation Report 84, April 13, 2020	No asymptomatic data	Various
97	Rothe C., et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany	No asymptomatic data	Germany
98	Korea CDC, COVID-19 National Emergency Response Center, E.a.C.M.T., Korea Centers for Disease Control and Prevention., Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea. Osong Public Health Res Perspect, 2020. 11(1): p. 8-14.	No asymptomatic data	Korea
99	Du, Z., et al., Serial Interval of COVID-19 among Publicly Reported Confirmed Cases. Emerg Infect Dis, 2020. 26(6).	No asymptomatic data	China
100	Ghinai, I., et al., First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet, 2020. 395(10230): p. 1137-1144.	No asymptomatic data	USA
101	Ping, K., Epidemiologic Characteristics of COVID-19 in Guizhou, China. 2020, medRxiv.	No asymptomatic data	China
102	Scott, S.E., et al., First Mildly Ill, Non-Hospitalized Case of Coronavirus Disease 2019 (COVID-19) Without Viral Transmission in the United States - Maricopa County, Arizona, 2020. Clin Infect Dis, 2020.	No asymptomatic data	USA
103	Qian, G., et al., A COVID-19 Transmission within a family cluster by presymptomatic infectors in China. Clin Infect Dis, 2020.	No asymptomatic data	China
104	Wei, W. Report, Presymptomatic Transmission of SARS-CoV-2—Singapore, January 23–March 16, 2020. 2020. 69.	No asymptomatic data	Singapore
105	Liu, Y., S. Funk, and S. Flasche, The contribution of pre-symptomatic infection to the transmission dynamics of COVID-2019. 2020. 5(58): p. 58.	No asymptomatic data	China
106	Aguilar, J., et al., Investigating the Impact of Asymptomatic Carriers on COVID-19 Transmission. 2020, medRxiv.	Modelling study	Various
107	Aleta, A. and Y. Moreno, Evaluation of the potential incidence of COVID-19 and effectiveness of contention measures in Spain: a data-driven approach. 2020, medRxiv.	Modelling study	Spain
108	Jing, Q., et al., Estimation of incubation period distribution of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up study. 2020, medRxiv.	Modelling study	China
109	Stock, J.H., et al., Estimates of the Undetected Rate among the SARS-CoV-2 Infected using Testing Data from Iceland. medRxiv, 2020: p. 2020.04.06.20055582.	Modelling study	Iceland
110	Serra M, Case studies of blood donors	insufficient data, Newspaper source,	Italy
111	Kimball A, et al., Asymptomatic and pre-symptomatic SARS-CoV-2 infections in residents of a Long-term care skilled nursing facility, Washington	Insufficient asymptomatic results	USA
112	Kim, E.S., et al., Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. J Korean Med Sci, 2020. 35(13): p. e142.	Insufficient asymptomatic results	Korea

113	Roxby, A et al. Report, Detection of SARS-CoV-2 Among Residents and Staff Members of an Independent and Assisted Living Community for Older Adults—Seattle, Washington, 2020. 2020. 69.	Insufficient asymptomatic results	USA
114	L'Huillier, A., et al., Shedding of infectious SARS-CoV-2 in symptomatic neonates, children and adolescents. 2020, medRxiv	Editorial	Switzerland
115	Black, J.R.M., et al., COVID-19: the case for health-care worker screening to prevent hospital transmission. <i>Lancet</i> , 2020. <b>395</b> (10234): p. 1418-1420.	Editorial	England
116	Gandhi, M., D.S. Yokoe, and D.V. Havlir, Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. <i>N Engl J Med</i> , 2020.	Editorial	Various
117	Gautret, P., et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. <i>Int J Antimicrob Agents</i> , 2020: p. 105949.	Asymptomatic results reported with sx	France
118	HaEmek Medical Center, I., Chloroquine for Mild Symptomatic and Asymptomatic COVID-19. <i>ClinicalTrials.gov</i> , 2020.	Trial protocol, no data	Israel
119	Centre Hospitalier Intercommunal, C., Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children. <i>ClinicalTrials.gov</i> , 2020.	Trial protocol, no data	France
120	Centre Hospitalier Intercommunal, C., Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children. <i>ClinicalTrials.gov</i> , 2020.	Trial protocol, no data	France
121	Mullins, E., et al., Coronavirus in pregnancy and delivery: rapid review. <i>Ultrasound Obstet Gynecol</i> , 2020.	Rapid review of case studies	Various
122	Al-Tawfiq, J.A., Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19). <i>Travel Med Infect Dis</i> , 2020: p. 101608.	MERS-CoV, no COVID-19	Various
123	Shaman, J. and M. Galanti, Direct Measurement of Rates of Asymptomatic Infection and Clinical Care-Seeking for Seasonal Coronavirus. 2020, medRxiv.	Flu 2018, no COVID-19	USA

### Supplement 3. Risk of bias assessment signalling questions

1. Was the sampling frame a true or close representation of the target population (all at risk of SARS-CoV-2 infection)?
  - 1a. What method of sampling was used? Complete sampling (census), Random selection, Other?
  - 1b. Is there likely to be bias from selection of a study population that doesn't match the target population (all at risk of the infection)?
2. Was there incomplete ascertainment of infection status in the study population?
  - 2a. Was a reference standard applied to everyone (or a random sample) of the study population? Is the probability of having a reference standard applied different for people without symptoms/mild symptoms/with severe symptoms?
  - 2b. Is there likely to be bias from incomplete ascertainment of infection status in the study population?
3. Were acceptable methods used to identify individuals in the study population who had SARS-CoV-2 infection (denominator for research question)?
  - 3a. What reference standards were used to determine SARS-CoV-2 infection status, and what is the estimated diagnostic accuracy for these? Did the choice of reference standard differ depending on whether or not symptoms were present, and the severity of symptoms?
  - 3b. Is there likely to be bias from differential application of reference standards to define infection status?
4. Was an acceptable case definition used in the study (numerator for the research question)?
  - 4a. What was the definition of asymptomatic infection? Was there distinction between asymptomatic and minimally symptomatic?
  - 4b. Is there likely to be bias from the definition of asymptomatic infection?
5. Was the length of follow-up to define case definition (asymptomatic infection) appropriate?
  - 5a. Was the follow-up of people without symptoms sufficient to allow for the incubation period, to allow classification as asymptomatic vs pre-symptomatic?
  - 5b. Is there likely to be bias from insufficient follow-up?